 | • レポートコード：MRC2-11QY00340 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、181ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はC-MET/HGF阻害剤のグローバル市場について調査・分析したレポートです。種類別（C-Met生物学的阻害剤、小分子C-Met阻害剤、HGF拮抗薬抗体、C-Met拮抗薬抗体（MetMAb）、HGFクリングル変異拮抗薬）市場規模、用途別（病院薬局、小売薬局、ドラッグストア、オンライン販売）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別C-MET/HGF阻害剤の競争状況、市場シェア ・世界のC-MET/HGF阻害剤市場：種類別市場規模 2015年-2020年（C-Met生物学的阻害剤、小分子C-Met阻害剤、HGF拮抗薬抗体、C-Met拮抗薬抗体（MetMAb）、HGFクリングル変異拮抗薬） ・世界のC-MET/HGF阻害剤市場：種類別市場規模予測 2021年-2026年（C-Met生物学的阻害剤、小分子C-Met阻害剤、HGF拮抗薬抗体、C-Met拮抗薬抗体（MetMAb）、HGFクリングル変異拮抗薬） ・世界のC-MET/HGF阻害剤市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、ドラッグストア、オンライン販売） ・世界のC-MET/HGF阻害剤市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、ドラッグストア、オンライン販売） ・北米のC-MET/HGF阻害剤市場分析：米国、カナダ ・ヨーロッパのC-MET/HGF阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのC-MET/HGF阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のC-MET/HGF阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのC-MET/HGF阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Abxign、Abbott Laboratories、Amgen、ArQule、Astex Therapeutics、AVEO Pharmaceuticals、Bristol-Myers Squibb(BMS)、Chroma Therapeutics、Daiichi Sankyo、Deciphera Pharmaceuticals、Eisai、Eli Lilly、Exelixis、Genmab、Galaxy Biotech、GlaxoSmithKline(GSK)、Hutchison MediPharma、Johnson & Johnson、Kringle Pharmaceuticals、Merck、Methylgene、Novartis、Pfizer、ProMetic BioTherapeutics、Takeda Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several biological responses collectively known as invasive growth program. These responses are elicited due to activation of several pathways such as RAS pathway, PI3K pathway, STAT pathway, beta-catenin pathway and Notch pathway. However, dysregulation of the HGF/c-MET signaling pathway has been associated with the progression of cancers through activation of oncogenic pathways, angiogenesis and metastasis.
The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF.
Market Analysis and Insights: Global C-MET / HGF Inhibitors Market
The global C-MET / HGF Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global C-MET / HGF Inhibitors Scope and Market Size
C-MET / HGF Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global C-MET / HGF Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the C-MET / HGF Inhibitors market is segmented into
C-Met Biologic Inhibitors
Small Molecule C-Met Inhibitors
HGF Antagonist Antibodies
C-Met Antagonist Antibodies(MetMAb)
HGF Kringle Variant Antagonists
Segment by Application, the C-MET / HGF Inhibitors market is segmented into
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Regional and Country-level Analysis
The C-MET / HGF Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the C-MET / HGF Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and C-MET / HGF Inhibitors Market Share Analysis
C-MET / HGF Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in C-MET / HGF Inhibitors business, the date to enter into the C-MET / HGF Inhibitors market, C-MET / HGF Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Abxign
Abbott Laboratories
Amgen
ArQule
Astex Therapeutics
AVEO Pharmaceuticals
Bristol-Myers Squibb(BMS)
Chroma Therapeutics
Daiichi Sankyo
Deciphera Pharmaceuticals
Eisai
Eli Lilly
Exelixis
Genmab
Galaxy Biotech
GlaxoSmithKline(GSK)
Hutchison MediPharma
Johnson & Johnson
Kringle Pharmaceuticals
Merck
Methylgene
Novartis
Pfizer
ProMetic BioTherapeutics
Takeda Pharmaceutical
1 Study Coverage
1.1 C-MET / HGF Inhibitors Product Introduction
1.2 Market Segments
1.3 Key C-MET / HGF Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global C-MET / HGF Inhibitors Market Size Growth Rate by Type
1.4.2 C-Met Biologic Inhibitors
1.4.3 Small Molecule C-Met Inhibitors
1.4.4 HGF Antagonist Antibodies
1.4.5 C-Met Antagonist Antibodies(MetMAb)
1.4.6 HGF Kringle Variant Antagonists
1.5 Market by Application
1.5.1 Global C-MET / HGF Inhibitors Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Drug Stores
1.5.5 Online Sales
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global C-MET / HGF Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global C-MET / HGF Inhibitors Revenue 2015-2026
2.1.2 Global C-MET / HGF Inhibitors Sales 2015-2026
2.2 Global C-MET / HGF Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global C-MET / HGF Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global C-MET / HGF Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global C-MET / HGF Inhibitors Competitor Landscape by Players
3.1 C-MET / HGF Inhibitors Sales by Manufacturers
3.1.1 C-MET / HGF Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 C-MET / HGF Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 C-MET / HGF Inhibitors Revenue by Manufacturers
3.2.1 C-MET / HGF Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 C-MET / HGF Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global C-MET / HGF Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by C-MET / HGF Inhibitors Revenue in 2019
3.2.5 Global C-MET / HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 C-MET / HGF Inhibitors Price by Manufacturers
3.4 C-MET / HGF Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 C-MET / HGF Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers C-MET / HGF Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into C-MET / HGF Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global C-MET / HGF Inhibitors Market Size by Type (2015-2020)
4.1.1 Global C-MET / HGF Inhibitors Sales by Type (2015-2020)
4.1.2 Global C-MET / HGF Inhibitors Revenue by Type (2015-2020)
4.1.3 C-MET / HGF Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global C-MET / HGF Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global C-MET / HGF Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global C-MET / HGF Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 C-MET / HGF Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global C-MET / HGF Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global C-MET / HGF Inhibitors Market Size by Application (2015-2020)
5.1.1 Global C-MET / HGF Inhibitors Sales by Application (2015-2020)
5.1.2 Global C-MET / HGF Inhibitors Revenue by Application (2015-2020)
5.1.3 C-MET / HGF Inhibitors Price by Application (2015-2020)
5.2 C-MET / HGF Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global C-MET / HGF Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global C-MET / HGF Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global C-MET / HGF Inhibitors Price Forecast by Application (2021-2026)
6 North America
6.1 North America C-MET / HGF Inhibitors by Country
6.1.1 North America C-MET / HGF Inhibitors Sales by Country
6.1.2 North America C-MET / HGF Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America C-MET / HGF Inhibitors Market Facts & Figures by Type
6.3 North America C-MET / HGF Inhibitors Market Facts & Figures by Application
7 Europe
7.1 Europe C-MET / HGF Inhibitors by Country
7.1.1 Europe C-MET / HGF Inhibitors Sales by Country
7.1.2 Europe C-MET / HGF Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe C-MET / HGF Inhibitors Market Facts & Figures by Type
7.3 Europe C-MET / HGF Inhibitors Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific C-MET / HGF Inhibitors by Region
8.1.1 Asia Pacific C-MET / HGF Inhibitors Sales by Region
8.1.2 Asia Pacific C-MET / HGF Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific C-MET / HGF Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific C-MET / HGF Inhibitors Market Facts & Figures by Application
9 Latin America
9.1 Latin America C-MET / HGF Inhibitors by Country
9.1.1 Latin America C-MET / HGF Inhibitors Sales by Country
9.1.2 Latin America C-MET / HGF Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America C-MET / HGF Inhibitors Market Facts & Figures by Type
9.3 Central & South America C-MET / HGF Inhibitors Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa C-MET / HGF Inhibitors by Country
10.1.1 Middle East and Africa C-MET / HGF Inhibitors Sales by Country
10.1.2 Middle East and Africa C-MET / HGF Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa C-MET / HGF Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa C-MET / HGF Inhibitors Market Facts & Figures by Application
11 Company Profiles
11.1 Abxign
11.1.1 Abxign Corporation Information
11.1.2 Abxign Description and Business Overview
11.1.3 Abxign Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Abxign C-MET / HGF Inhibitors Products Offered
11.1.5 Abxign Related Developments
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Corporation Information
11.2.2 Abbott Laboratories Description and Business Overview
11.2.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Abbott Laboratories C-MET / HGF Inhibitors Products Offered
11.2.5 Abbott Laboratories Related Developments
11.3 Amgen
11.3.1 Amgen Corporation Information
11.3.2 Amgen Description and Business Overview
11.3.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Amgen C-MET / HGF Inhibitors Products Offered
11.3.5 Amgen Related Developments
11.4 ArQule
11.4.1 ArQule Corporation Information
11.4.2 ArQule Description and Business Overview
11.4.3 ArQule Sales, Revenue and Gross Margin (2015-2020)
11.4.4 ArQule C-MET / HGF Inhibitors Products Offered
11.4.5 ArQule Related Developments
11.5 Astex Therapeutics
11.5.1 Astex Therapeutics Corporation Information
11.5.2 Astex Therapeutics Description and Business Overview
11.5.3 Astex Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Astex Therapeutics C-MET / HGF Inhibitors Products Offered
11.5.5 Astex Therapeutics Related Developments
11.6 AVEO Pharmaceuticals
11.6.1 AVEO Pharmaceuticals Corporation Information
11.6.2 AVEO Pharmaceuticals Description and Business Overview
11.6.3 AVEO Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.6.4 AVEO Pharmaceuticals C-MET / HGF Inhibitors Products Offered
11.6.5 AVEO Pharmaceuticals Related Developments
11.7 Bristol-Myers Squibb(BMS)
11.7.1 Bristol-Myers Squibb(BMS) Corporation Information
11.7.2 Bristol-Myers Squibb(BMS) Description and Business Overview
11.7.3 Bristol-Myers Squibb(BMS) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Products Offered
11.7.5 Bristol-Myers Squibb(BMS) Related Developments
11.8 Chroma Therapeutics
11.8.1 Chroma Therapeutics Corporation Information
11.8.2 Chroma Therapeutics Description and Business Overview
11.8.3 Chroma Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Chroma Therapeutics C-MET / HGF Inhibitors Products Offered
11.8.5 Chroma Therapeutics Related Developments
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Corporation Information
11.9.2 Daiichi Sankyo Description and Business Overview
11.9.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Daiichi Sankyo C-MET / HGF Inhibitors Products Offered
11.9.5 Daiichi Sankyo Related Developments
11.10 Deciphera Pharmaceuticals
11.10.1 Deciphera Pharmaceuticals Corporation Information
11.10.2 Deciphera Pharmaceuticals Description and Business Overview
11.10.3 Deciphera Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Products Offered
11.10.5 Deciphera Pharmaceuticals Related Developments
11.1 Abxign
11.1.1 Abxign Corporation Information
11.1.2 Abxign Description and Business Overview
11.1.3 Abxign Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Abxign C-MET / HGF Inhibitors Products Offered
11.1.5 Abxign Related Developments
11.12 Eli Lilly
11.12.1 Eli Lilly Corporation Information
11.12.2 Eli Lilly Description and Business Overview
11.12.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Eli Lilly Products Offered
11.12.5 Eli Lilly Related Developments
11.13 Exelixis
11.13.1 Exelixis Corporation Information
11.13.2 Exelixis Description and Business Overview
11.13.3 Exelixis Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Exelixis Products Offered
11.13.5 Exelixis Related Developments
11.14 Genmab
11.14.1 Genmab Corporation Information
11.14.2 Genmab Description and Business Overview
11.14.3 Genmab Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Genmab Products Offered
11.14.5 Genmab Related Developments
11.15 Galaxy Biotech
11.15.1 Galaxy Biotech Corporation Information
11.15.2 Galaxy Biotech Description and Business Overview
11.15.3 Galaxy Biotech Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Galaxy Biotech Products Offered
11.15.5 Galaxy Biotech Related Developments
11.16 GlaxoSmithKline(GSK)
11.16.1 GlaxoSmithKline(GSK) Corporation Information
11.16.2 GlaxoSmithKline(GSK) Description and Business Overview
11.16.3 GlaxoSmithKline(GSK) Sales, Revenue and Gross Margin (2015-2020)
11.16.4 GlaxoSmithKline(GSK) Products Offered
11.16.5 GlaxoSmithKline(GSK) Related Developments
11.17 Hutchison MediPharma
11.17.1 Hutchison MediPharma Corporation Information
11.17.2 Hutchison MediPharma Description and Business Overview
11.17.3 Hutchison MediPharma Sales, Revenue and Gross Margin (2015-2020)
11.17.4 Hutchison MediPharma Products Offered
11.17.5 Hutchison MediPharma Related Developments
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Corporation Information
11.18.2 Johnson & Johnson Description and Business Overview
11.18.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Johnson & Johnson Products Offered
11.18.5 Johnson & Johnson Related Developments
11.19 Kringle Pharmaceuticals
11.19.1 Kringle Pharmaceuticals Corporation Information
11.19.2 Kringle Pharmaceuticals Description and Business Overview
11.19.3 Kringle Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Kringle Pharmaceuticals Products Offered
11.19.5 Kringle Pharmaceuticals Related Developments
11.20 Merck
11.20.1 Merck Corporation Information
11.20.2 Merck Description and Business Overview
11.20.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Merck Products Offered
11.20.5 Merck Related Developments
11.21 Methylgene
11.21.1 Methylgene Corporation Information
11.21.2 Methylgene Description and Business Overview
11.21.3 Methylgene Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Methylgene Products Offered
11.21.5 Methylgene Related Developments
11.22 Novartis
11.22.1 Novartis Corporation Information
11.22.2 Novartis Description and Business Overview
11.22.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Novartis Products Offered
11.22.5 Novartis Related Developments
11.23 Pfizer
11.23.1 Pfizer Corporation Information
11.23.2 Pfizer Description and Business Overview
11.23.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Pfizer Products Offered
11.23.5 Pfizer Related Developments
11.24 ProMetic BioTherapeutics
11.24.1 ProMetic BioTherapeutics Corporation Information
11.24.2 ProMetic BioTherapeutics Description and Business Overview
11.24.3 ProMetic BioTherapeutics Sales, Revenue and Gross Margin (2015-2020)
11.24.4 ProMetic BioTherapeutics Products Offered
11.24.5 ProMetic BioTherapeutics Related Developments
11.25 Takeda Pharmaceutical
11.25.1 Takeda Pharmaceutical Corporation Information
11.25.2 Takeda Pharmaceutical Description and Business Overview
11.25.3 Takeda Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.25.4 Takeda Pharmaceutical Products Offered
11.25.5 Takeda Pharmaceutical Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 C-MET / HGF Inhibitors Market Estimates and Projections by Region
12.1.1 Global C-MET / HGF Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global C-MET / HGF Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America C-MET / HGF Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: C-MET / HGF Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: C-MET / HGF Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: C-MET / HGF Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe C-MET / HGF Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: C-MET / HGF Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: C-MET / HGF Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: C-MET / HGF Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific C-MET / HGF Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: C-MET / HGF Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: C-MET / HGF Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: C-MET / HGF Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America C-MET / HGF Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: C-MET / HGF Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: C-MET / HGF Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: C-MET / HGF Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa C-MET / HGF Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: C-MET / HGF Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: C-MET / HGF Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: C-MET / HGF Inhibitors Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key C-MET / HGF Inhibitors Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 C-MET / HGF Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. C-MET / HGF Inhibitors Market Segments
Table 2. Ranking of Global Top C-MET / HGF Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global C-MET / HGF Inhibitors Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of C-Met Biologic Inhibitors
Table 5. Major Manufacturers of Small Molecule C-Met Inhibitors
Table 6. Major Manufacturers of HGF Antagonist Antibodies
Table 7. Major Manufacturers of C-Met Antagonist Antibodies(MetMAb)
Table 8. Major Manufacturers of HGF Kringle Variant Antagonists
Table 9. Global C-MET / HGF Inhibitors Market Size Growth Rate by Application 2020-2026 (K MT)
Table 10. Global C-MET / HGF Inhibitors Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 11. Global C-MET / HGF Inhibitors Sales by Regions 2015-2020 (K MT)
Table 12. Global C-MET / HGF Inhibitors Sales Market Share by Regions (2015-2020)
Table 13. Global C-MET / HGF Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global C-MET / HGF Inhibitors Sales by Manufacturers (2015-2020) (K MT)
Table 15. Global C-MET / HGF Inhibitors Sales Share by Manufacturers (2015-2020)
Table 16. Global C-MET / HGF Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global C-MET / HGF Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in C-MET / HGF Inhibitors as of 2019)
Table 18. C-MET / HGF Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. C-MET / HGF Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers C-MET / HGF Inhibitors Price (2015-2020) (USD/MT)
Table 21. C-MET / HGF Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers C-MET / HGF Inhibitors Product Type
Table 23. Date of International Manufacturers Enter into C-MET / HGF Inhibitors Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global C-MET / HGF Inhibitors Sales by Type (2015-2020) (K MT)
Table 26. Global C-MET / HGF Inhibitors Sales Share by Type (2015-2020)
Table 27. Global C-MET / HGF Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 28. Global C-MET / HGF Inhibitors Revenue Share by Type (2015-2020)
Table 29. C-MET / HGF Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 30. Global C-MET / HGF Inhibitors Sales by Application (2015-2020) (K MT)
Table 31. Global C-MET / HGF Inhibitors Sales Share by Application (2015-2020)
Table 32. North America C-MET / HGF Inhibitors Sales by Country (2015-2020) (K MT)
Table 33. North America C-MET / HGF Inhibitors Sales Market Share by Country (2015-2020)
Table 34. North America C-MET / HGF Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 35. North America C-MET / HGF Inhibitors Revenue Market Share by Country (2015-2020)
Table 36. North America C-MET / HGF Inhibitors Sales by Type (2015-2020) (K MT)
Table 37. North America C-MET / HGF Inhibitors Sales Market Share by Type (2015-2020)
Table 38. North America C-MET / HGF Inhibitors Sales by Application (2015-2020) (K MT)
Table 39. North America C-MET / HGF Inhibitors Sales Market Share by Application (2015-2020)
Table 40. Europe C-MET / HGF Inhibitors Sales by Country (2015-2020) (K MT)
Table 41. Europe C-MET / HGF Inhibitors Sales Market Share by Country (2015-2020)
Table 42. Europe C-MET / HGF Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe C-MET / HGF Inhibitors Revenue Market Share by Country (2015-2020)
Table 44. Europe C-MET / HGF Inhibitors Sales by Type (2015-2020) (K MT)
Table 45. Europe C-MET / HGF Inhibitors Sales Market Share by Type (2015-2020)
Table 46. Europe C-MET / HGF Inhibitors Sales by Application (2015-2020) (K MT)
Table 47. Europe C-MET / HGF Inhibitors Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific C-MET / HGF Inhibitors Sales by Region (2015-2020) (K MT)
Table 49. Asia Pacific C-MET / HGF Inhibitors Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific C-MET / HGF Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific C-MET / HGF Inhibitors Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific C-MET / HGF Inhibitors Sales by Type (2015-2020) (K MT)
Table 53. Asia Pacific C-MET / HGF Inhibitors Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific C-MET / HGF Inhibitors Sales by Application (2015-2020) (K MT)
Table 55. Asia Pacific C-MET / HGF Inhibitors Sales Market Share by Application (2015-2020)
Table 56. Latin America C-MET / HGF Inhibitors Sales by Country (2015-2020) (K MT)
Table 57. Latin America C-MET / HGF Inhibitors Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa C-MET / HGF Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America C-MET / HGF Inhibitors Revenue Market Share by Country (2015-2020)
Table 60. Latin America C-MET / HGF Inhibitors Sales by Type (2015-2020) (K MT)
Table 61. Latin America C-MET / HGF Inhibitors Sales Market Share by Type (2015-2020)
Table 62. Latin America C-MET / HGF Inhibitors Sales by Application (2015-2020) (K MT)
Table 63. Latin America C-MET / HGF Inhibitors Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa C-MET / HGF Inhibitors Sales by Country (2015-2020) (K MT)
Table 65. Middle East and Africa C-MET / HGF Inhibitors Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa C-MET / HGF Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa C-MET / HGF Inhibitors Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa C-MET / HGF Inhibitors Sales by Type (2015-2020) (K MT)
Table 69. Middle East and Africa C-MET / HGF Inhibitors Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa C-MET / HGF Inhibitors Sales by Application (2015-2020) (K MT)
Table 71. Middle East and Africa C-MET / HGF Inhibitors Sales Market Share by Application (2015-2020)
Table 72. Abxign Corporation Information
Table 73. Abxign Description and Major Businesses
Table 74. Abxign C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 75. Abxign Product
Table 76. Abxign Recent Development
Table 77. Abbott Laboratories Corporation Information
Table 78. Abbott Laboratories Description and Major Businesses
Table 79. Abbott Laboratories C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 80. Abbott Laboratories Product
Table 81. Abbott Laboratories Recent Development
Table 82. Amgen Corporation Information
Table 83. Amgen Description and Major Businesses
Table 84. Amgen C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 85. Amgen Product
Table 86. Amgen Recent Development
Table 87. ArQule Corporation Information
Table 88. ArQule Description and Major Businesses
Table 89. ArQule C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 90. ArQule Product
Table 91. ArQule Recent Development
Table 92. Astex Therapeutics Corporation Information
Table 93. Astex Therapeutics Description and Major Businesses
Table 94. Astex Therapeutics C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 95. Astex Therapeutics Product
Table 96. Astex Therapeutics Recent Development
Table 97. AVEO Pharmaceuticals Corporation Information
Table 98. AVEO Pharmaceuticals Description and Major Businesses
Table 99. AVEO Pharmaceuticals C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 100. AVEO Pharmaceuticals Product
Table 101. AVEO Pharmaceuticals Recent Development
Table 102. Bristol-Myers Squibb(BMS) Corporation Information
Table 103. Bristol-Myers Squibb(BMS) Description and Major Businesses
Table 104. Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 105. Bristol-Myers Squibb(BMS) Product
Table 106. Bristol-Myers Squibb(BMS) Recent Development
Table 107. Chroma Therapeutics Corporation Information
Table 108. Chroma Therapeutics Description and Major Businesses
Table 109. Chroma Therapeutics C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 110. Chroma Therapeutics Product
Table 111. Chroma Therapeutics Recent Development
Table 112. Daiichi Sankyo Corporation Information
Table 113. Daiichi Sankyo Description and Major Businesses
Table 114. Daiichi Sankyo C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 115. Daiichi Sankyo Product
Table 116. Daiichi Sankyo Recent Development
Table 117. Deciphera Pharmaceuticals Corporation Information
Table 118. Deciphera Pharmaceuticals Description and Major Businesses
Table 119. Deciphera Pharmaceuticals C-MET / HGF Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 120. Deciphera Pharmaceuticals Product
Table 121. Deciphera Pharmaceuticals Recent Development
Table 122. Eisai Corporation Information
Table 123. Eisai Description and Major Businesses
Table 124. Eisai C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 125. Eisai Product
Table 126. Eisai Recent Development
Table 127. Eli Lilly Corporation Information
Table 128. Eli Lilly Description and Major Businesses
Table 129. Eli Lilly C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 130. Eli Lilly Product
Table 131. Eli Lilly Recent Development
Table 132. Exelixis Corporation Information
Table 133. Exelixis Description and Major Businesses
Table 134. Exelixis C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 135. Exelixis Product
Table 136. Exelixis Recent Development
Table 137. Genmab Corporation Information
Table 138. Genmab Description and Major Businesses
Table 139. Genmab C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 140. Genmab Product
Table 141. Genmab Recent Development
Table 142. Galaxy Biotech Corporation Information
Table 143. Galaxy Biotech Description and Major Businesses
Table 144. Galaxy Biotech C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 145. Galaxy Biotech Product
Table 146. Galaxy Biotech Recent Development
Table 147. GlaxoSmithKline(GSK) Corporation Information
Table 148. GlaxoSmithKline(GSK) Description and Major Businesses
Table 149. GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 150. GlaxoSmithKline(GSK) Product
Table 151. GlaxoSmithKline(GSK) Recent Development
Table 152. Hutchison MediPharma Corporation Information
Table 153. Hutchison MediPharma Description and Major Businesses
Table 154. Hutchison MediPharma C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 155. Hutchison MediPharma Product
Table 156. Hutchison MediPharma Recent Development
Table 157. Johnson & Johnson Corporation Information
Table 158. Johnson & Johnson Description and Major Businesses
Table 159. Johnson & Johnson C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 160. Johnson & Johnson Product
Table 161. Johnson & Johnson Recent Development
Table 162. Kringle Pharmaceuticals Corporation Information
Table 163. Kringle Pharmaceuticals Description and Major Businesses
Table 164. Kringle Pharmaceuticals C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 165. Kringle Pharmaceuticals Product
Table 166. Kringle Pharmaceuticals Recent Development
Table 167. Merck Corporation Information
Table 168. Merck Description and Major Businesses
Table 169. Merck C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 170. Merck Product
Table 171. Merck Recent Development
Table 172. Methylgene Corporation Information
Table 173. Methylgene Description and Major Businesses
Table 174. Methylgene C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 175. Methylgene Product
Table 176. Methylgene Recent Development
Table 177. Novartis Corporation Information
Table 178. Novartis Description and Major Businesses
Table 179. Novartis C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 180. Novartis Product
Table 181. Novartis Recent Development
Table 182. Pfizer Corporation Information
Table 183. Pfizer Description and Major Businesses
Table 184. Pfizer C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 185. Pfizer Product
Table 186. Pfizer Recent Development
Table 187. ProMetic BioTherapeutics Corporation Information
Table 188. ProMetic BioTherapeutics Description and Major Businesses
Table 189. ProMetic BioTherapeutics C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 190. ProMetic BioTherapeutics Product
Table 191. ProMetic BioTherapeutics Recent Development
Table 192. Takeda Pharmaceutical Corporation Information
Table 193. Takeda Pharmaceutical Description and Major Businesses
Table 194. Takeda Pharmaceutical C-MET / HGF Inhibitors Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 195. Takeda Pharmaceutical Product
Table 196. Takeda Pharmaceutical Recent Development
Table 197. Global C-MET / HGF Inhibitors Sales Forecast by Regions (2021-2026) (K MT)
Table 198. Global C-MET / HGF Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 199. Global C-MET / HGF Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 200. Global C-MET / HGF Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 201. North America: C-MET / HGF Inhibitors Sales Forecast by Country (2021-2026) (K MT)
Table 202. North America: C-MET / HGF Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 203. Europe: C-MET / HGF Inhibitors Sales Forecast by Country (2021-2026) (K MT)
Table 204. Europe: C-MET / HGF Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 205. Asia Pacific: C-MET / HGF Inhibitors Sales Forecast by Region (2021-2026) (K MT)
Table 206. Asia Pacific: C-MET / HGF Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 207. Latin America: C-MET / HGF Inhibitors Sales Forecast by Country (2021-2026) (K MT)
Table 208. Latin America: C-MET / HGF Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 209. Middle East and Africa: C-MET / HGF Inhibitors Sales Forecast by Country (2021-2026) (K MT)
Table 210. Middle East and Africa: C-MET / HGF Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 211. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 212. Key Challenges
Table 213. Market Risks
Table 214. Main Points Interviewed from Key C-MET / HGF Inhibitors Players
Table 215. C-MET / HGF Inhibitors Customers List
Table 216. C-MET / HGF Inhibitors Distributors List
Table 217. Research Programs/Design for This Report
Table 218. Key Data Information from Secondary Sources
Table 219. Key Data Information from Primary Sources
List of Figures
Figure 1. C-MET / HGF Inhibitors Product Picture
Figure 2. Global C-MET / HGF Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. C-Met Biologic Inhibitors Product Picture
Figure 4. Small Molecule C-Met Inhibitors Product Picture
Figure 5. HGF Antagonist Antibodies Product Picture
Figure 6. C-Met Antagonist Antibodies(MetMAb) Product Picture
Figure 7. HGF Kringle Variant Antagonists Product Picture
Figure 8. Global C-MET / HGF Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Drug Stores
Figure 12. Online Sales
Figure 13. C-MET / HGF Inhibitors Report Years Considered
Figure 14. Global C-MET / HGF Inhibitors Market Size 2015-2026 (US$ Million)
Figure 15. Global C-MET / HGF Inhibitors Sales 2015-2026 (K MT)
Figure 16. Global C-MET / HGF Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global C-MET / HGF Inhibitors Sales Market Share by Region (2015-2020)
Figure 18. Global C-MET / HGF Inhibitors Sales Market Share by Region in 2019
Figure 19. Global C-MET / HGF Inhibitors Revenue Market Share by Region (2015-2020)
Figure 20. Global C-MET / HGF Inhibitors Revenue Market Share by Region in 2019
Figure 21. Global C-MET / HGF Inhibitors Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by C-MET / HGF Inhibitors Revenue in 2019
Figure 23. C-MET / HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global C-MET / HGF Inhibitors Sales Market Share by Type (2015-2020)
Figure 25. Global C-MET / HGF Inhibitors Sales Market Share by Type in 2019
Figure 26. Global C-MET / HGF Inhibitors Revenue Market Share by Type (2015-2020)
Figure 27. Global C-MET / HGF Inhibitors Revenue Market Share by Type in 2019
Figure 28. Global C-MET / HGF Inhibitors Market Share by Price Range (2015-2020)
Figure 29. Global C-MET / HGF Inhibitors Sales Market Share by Application (2015-2020)
Figure 30. Global C-MET / HGF Inhibitors Sales Market Share by Application in 2019
Figure 31. Global C-MET / HGF Inhibitors Revenue Market Share by Application (2015-2020)
Figure 32. Global C-MET / HGF Inhibitors Revenue Market Share by Application in 2019
Figure 33. North America C-MET / HGF Inhibitors Sales Growth Rate 2015-2020 (K MT)
Figure 34. North America C-MET / HGF Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America C-MET / HGF Inhibitors Sales Market Share by Country in 2019
Figure 36. North America C-MET / HGF Inhibitors Revenue Market Share by Country in 2019
Figure 37. U.S. C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 38. U.S. C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 40. Canada C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America C-MET / HGF Inhibitors Market Share by Type in 2019
Figure 42. North America C-MET / HGF Inhibitors Market Share by Application in 2019
Figure 43. Europe C-MET / HGF Inhibitors Sales Growth Rate 2015-2020 (K MT)
Figure 44. Europe C-MET / HGF Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe C-MET / HGF Inhibitors Sales Market Share by Country in 2019
Figure 46. Europe C-MET / HGF Inhibitors Revenue Market Share by Country in 2019
Figure 47. Germany C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 48. Germany C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 50. France C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 52. U.K. C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 54. Italy C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 56. Russia C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe C-MET / HGF Inhibitors Market Share by Type in 2019
Figure 58. Europe C-MET / HGF Inhibitors Market Share by Application in 2019
Figure 59. Asia Pacific C-MET / HGF Inhibitors Sales Growth Rate 2015-2020 (K MT)
Figure 60. Asia Pacific C-MET / HGF Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific C-MET / HGF Inhibitors Sales Market Share by Region in 2019
Figure 62. Asia Pacific C-MET / HGF Inhibitors Revenue Market Share by Region in 2019
Figure 63. China C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 64. China C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 66. Japan C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 68. South Korea C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 70. India C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 72. Australia C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 74. Taiwan C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 76. Indonesia C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 78. Thailand C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 80. Malaysia C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 82. Philippines C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 84. Vietnam C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific C-MET / HGF Inhibitors Market Share by Type in 2019
Figure 86. Asia Pacific C-MET / HGF Inhibitors Market Share by Application in 2019
Figure 87. Latin America C-MET / HGF Inhibitors Sales Growth Rate 2015-2020 (K MT)
Figure 88. Latin America C-MET / HGF Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America C-MET / HGF Inhibitors Sales Market Share by Country in 2019
Figure 90. Latin America C-MET / HGF Inhibitors Revenue Market Share by Country in 2019
Figure 91. Mexico C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 92. Mexico C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 94. Brazil C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 96. Argentina C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America C-MET / HGF Inhibitors Market Share by Type in 2019
Figure 98. Latin America C-MET / HGF Inhibitors Market Share by Application in 2019
Figure 99. Middle East and Africa C-MET / HGF Inhibitors Sales Growth Rate 2015-2020 (K MT)
Figure 100. Middle East and Africa C-MET / HGF Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa C-MET / HGF Inhibitors Sales Market Share by Country in 2019
Figure 102. Middle East and Africa C-MET / HGF Inhibitors Revenue Market Share by Country in 2019
Figure 103. Turkey C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 104. Turkey C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 106. Saudi Arabia C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E C-MET / HGF Inhibitors Sales Growth Rate (2015-2020) (K MT)
Figure 108. U.A.E C-MET / HGF Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa C-MET / HGF Inhibitors Market Share by Type in 2019
Figure 110. Middle East and Africa C-MET / HGF Inhibitors Market Share by Application in 2019
Figure 111. North America C-MET / HGF Inhibitors Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. North America C-MET / HGF Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe C-MET / HGF Inhibitors Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Europe C-MET / HGF Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific C-MET / HGF Inhibitors Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Asia Pacific C-MET / HGF Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America C-MET / HGF Inhibitors Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. Latin America C-MET / HGF Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa C-MET / HGF Inhibitors Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 120. Middle East and Africa C-MET / HGF Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
TNF阻害剤の世界市場（～2026年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…- シグナル伝達阻害剤の世界市場（～2026年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…
- DPP IV阻害剤（DPP-4阻害剤）の世界市場（～2026年） DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of in…
- プロテアソーム阻害剤の世界市場（～2026年） Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins. Proteasome inhibitors are being studied in the treatment of cancer and are used in treating multiple myeloma. Market Analysis and Insights: Global Proteasome Inhibitors Market The globa…
- 重合阻害剤の世界市場（～2026年） Monomers are often stabilized by the addition of inhibitors to prevent polymerization initiation by light, heat and air. Asia Pacific is estimated to be the fastest growing region in the global polymerization inhibitors market owing to increasing demand for it. Market Analysis and Insights: Global P…